Mvumbi Dieudonné Makaba, Bobanga Thierry Lengu, Kayembe Jean-Marie Ntumba, Mvumbi Georges Lelo, Situakibanza Hippolyte Nani-Tuma, Benoit-Vical Françoise, Melin Pierrette, De Mol Patrick, Hayette Marie-Pierre
Biochemistry and Molecular Biology Unit, Department of Basic Sciences, School of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Department of Clinical Microbiology, University Hospital of Liege, Liege, Belgium.
PLoS One. 2017 Jun 8;12(6):e0179142. doi: 10.1371/journal.pone.0179142. eCollection 2017.
Malaria is a major public health problem in the Democratic Republic of Congo. Despite progress achieved over the past decade in the fight against malaria, further efforts have to be done such as in the surveillance and the containment of Plasmodium falciparum resistant strains. We investigated resistance to artemisinin-based combination therapies currently in use in Democratic Republic of Congo by surveying molecular polymorphisms in three genes: pfcrt, pfmdr1 and pfk13 to explore possible emergence of amodiaquine, lumefantrine or artemisinin resistance in Democratic Republic of Congo. This study essentially revealed that resistance to chloroquine is still decreasing while polymorphism related to amodiaquine resistance seems to be not present in Democratic Republic of Congo, that three samples, located in the east of the country, harbor Pfmdr1 amplification and that none of the mutations found in South-East Asia correlated with artemisinine resistance have been found in Democratic Republic of Congo. But new mutations have been identified, especially the M476K, occurred in the same position that the M476I previously identified in the F32-ART strain, strongly resistant to artemisinine. Antimalarial first-line treatments currently in use in Democratic Republic of Congo are not associated with emergence of molecular markers of resistance.
疟疾是刚果民主共和国的一个主要公共卫生问题。尽管在过去十年抗击疟疾方面取得了进展，但仍需进一步努力，如监测和控制恶性疟原虫耐药菌株。我们通过调查三个基因（pfcrt、pfmdr1和pfk13）中的分子多态性，研究了刚果民主共和国目前使用的基于青蒿素的联合疗法的耐药情况，以探索该国可能出现的对阿莫地喹、本芴醇或青蒿素的耐药性。这项研究基本上揭示，对氯喹的耐药性仍在下降，而与阿莫地喹耐药性相关的多态性在刚果民主共和国似乎不存在，该国东部的三个样本存在Pfmdr1扩增，并且在刚果民主共和国未发现东南亚发现的与青蒿素耐药性相关的任何突变。但已鉴定出一些新突变，特别是M476K，其发生位置与先前在对青蒿素高度耐药的F32-ART菌株中鉴定出的M476I相同。刚果民主共和国目前使用的一线抗疟治疗与耐药分子标志物的出现无关。
